Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 6/20 | 0.52 |
| ▸ | METAP1 | P53582 | 1/20 | 0.46 |
| ▸ | SETDB1 | Q15047 | 1/20 | 0.45 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5033185 | 0.85 | NCF1 (0.57) | NCF1ADRB2ADRB1MAPTCHRM4 | |
| SCHEMBL5037445 | 0.82 | NCF1 (0.53) | NCF1ADRB2ADRB1MAPTCHRM4 | |
| SCHEMBL5037355 | 0.82 | NCF1 (0.53) | NCF1ADRB2ADRB1MAPTMAPK1 | |
| SCHEMBL5036066 | 0.82 | NCF1 (0.53) | NCF1ADRB2ADRB1MAPTMAPK1 | |
| SCHEMBL5035794 | 0.81 | NCF1 (0.52) | NCF1ADRB2ADRB1MAPTMAOA | |
| Hydrochloric Acid SCHEMBL5037491 | 0.81 | NCF1 (0.52) | NCF1ADRB2ADRB1MAPTCHRM4 | |
| Hydrochloric Acid SCHEMBL5033319 | 0.81 | NCF1 (0.52) | NCF1ADRB2ADRB1MAPTMAPK1 | |
| SCHEMBL5036263 | 0.81 | NCF1 (0.61) | NCF1ADRB2ADRB1MAPTKMT2A | |
| SCHEMBL5033351 | 0.80 | NCF1 (0.61) | NCF1ADRB2ADRB1MAPTMAPK1 | |
| Hydrochloric Acid SCHEMBL5033349 | 0.80 | NCF1 (0.51) | NCF1ADRB2ADRB1MAPTMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1395564-B1 | QUINOLINE DERIVATIVES AS LIGANDS FOR THE NEUROPEPTIDE Y RECEPTOR | HOFFMANN LA ROCHE (CH) | 2008-02-27 | — | — | EP | disclosed |
| US-20050049413-A1 | Quinoline derivatives | MUELLER WERNER (CH) | 2005-03-03 | — | — | US | disclosed |
| US-6818767-B2 | NEUROPEPTIDE Y (NPY) ANTAGONISTS FOR THE TREATMENT OR PREVENTION OF ARTHRITIS, CARDIOVASCULAR DISEASES, DIABETES, RENAL FAILURE, EATING DISORDERS, OR OBESITY | HOFFMANN-LA ROCHE INC. | 2004-11-16 | — | — | US | disclosed |
| US-20020198194-A1 | Quinoline derivatives | HOFFMANN-LA ROCHE INC. | 2002-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198194-A1 | Quinoline derivatives | NPY2R, NPY1R, NPY4R | NCF1 1052/4885METAP1 2800/4885SETDB1 4775/4885 |
| US-20050049413-A1 | Quinoline derivatives | NPY2R, NPY1R, NPY4R | NCF1 1052/4885METAP1 2800/4885SETDB1 4775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.